<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720521</url>
  </required_header>
  <id_info>
    <org_study_id>OE2021</org_study_id>
    <nct_id>NCT04720521</nct_id>
  </id_info>
  <brief_title>Application of OE in Diagnosis of EGC</brief_title>
  <official_title>Application of OpticalEnhancement Endoscopy（OE） in Diagnosis of Early Gastric Cancer: a Multicenter, Prospective, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Central Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Tongji Hospital, Tongji University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sino-Japanese Friendship Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Guangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate application value of OE mode 2 in the diagnosis&#xD;
      of early gastric cancer The Secondary purpose is to evaluate application value of OE mode 1&#xD;
      in differentiating the diagnosis of neoplastic lesions of the gastric mucosa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is the most prevalent cancer in China，while the detection rate of early&#xD;
      gastric cancer is lower than 10%. An effective screening method to improve the detection rate&#xD;
      is urgently needed. Optical Enhancement (OE) mode is an endoscopic mode that uses the&#xD;
      principle of grating for electronic staining, which provides a clear picture of the&#xD;
      submucosal and superficial mucosal vascular structures. The OE1 mode provides enhanced images&#xD;
      of the gastric Gland tube and blood vessels, as well as magnification. The OE2 mode is used&#xD;
      to identify small chromatic aberrations and to visualize superficial structures in the&#xD;
      gastric mucosa. So we designed this randomized controlled trial to discuss effectiveness of&#xD;
      OE in the diagnosis of early gastric cancer and we hope to find an effective method to&#xD;
      improve the detection rate of early gastric cancer in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">May 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of gastric neoplastic lesion</measure>
    <time_frame>procedure</time_frame>
    <description>Include early gastric cancer, high-grade neoplasia, low-grade neoplasia and adenoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity of detecting gastric neoplastic lesion</measure>
    <time_frame>procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of detecting gastric neoplastic lesion</measure>
    <time_frame>procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2454</enrollment>
  <condition>High Risk Population of Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>OE+white light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using white light firstly to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>White light</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Using White light to observe from esophagus to duodenum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OE+white light</intervention_name>
    <description>Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus</description>
    <arm_group_label>OE+white light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Meet item 1or 2 + any items of 3-7&#xD;
&#xD;
          1. Male ≥ 40 years old, female ≥ 50 years old.&#xD;
&#xD;
          2. More than one year since the last gastroscopy.&#xD;
&#xD;
          3. Patients from the areas with high incidence of stomach cancer (Shandong Province,&#xD;
             Liaoning Province, Fujian Province, Gansu Province, Qinghai Province, Ningxia&#xD;
             Province, Jilin Province, Jiangsu Province, Shanghai).&#xD;
&#xD;
          4. Patients with pre-cancerous gastric diseases such as chronic atrophic gastritis,&#xD;
             gastric ulcer, gastric polyp, hypertrophic gastritis, pernicious anemia, etc. in the&#xD;
             past.&#xD;
&#xD;
          5. First-degree relatives of patients with a family history of gastric cancer.&#xD;
&#xD;
          6. Other high-risk life factors for gastric cancer (high salt, pickled diet, smoking,&#xD;
             heavy alcohol consumption, etc.)&#xD;
&#xD;
          7. Positive serum gastric function tests (GastroPanel) include: H. pylori (H.P) antibody&#xD;
             （+）, Fasting pepsinogen I and II ratio (PG I/PGII) &lt;3.89, gastrin 17 (G-17) &gt;1.50&#xD;
             pmol/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have undergone invasive treatment such as surgical resection, PEG,&#xD;
             chemotherapy etc. of either stomach or oesophagus. (except for EMR and ESD).&#xD;
&#xD;
          2. Patients with a confirmed diagnosis of progressive cancer above T2 degreed according&#xD;
             to the TMN classification of cancer。&#xD;
&#xD;
          3. Patients on anticoagulants that cannot be biopsied.&#xD;
&#xD;
          4. Patients who have undergone gastrectomy.&#xD;
&#xD;
          5. Patients who have taken PPIs or H2 receptor antagonist within two weeks.&#xD;
&#xD;
          6. Patients with history of malignant neoplasm; high suspicion of neoplasm; severe&#xD;
             cardiac, pulmonary, hepatic or renal insufficiency; severe mental illness and pregnant&#xD;
             women.&#xD;
&#xD;
          7. Patients who did not signed the consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhao shen Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastroenterology, Changhai Hospital, Second Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang hao Hu, M.D.</last_name>
    <phone>8613817593520</phone>
    <email>lianghao-hu@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Di Zhang, M.D.</last_name>
    <phone>8613162039421</phone>
    <email>hugh_zd@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastroenterology, Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Gomez JM, Wang AY. Gastric intestinal metaplasia and early gastric cancer in the west: a changing paradigm. Gastroenterol Hepatol (N Y). 2014 Jun;10(6):369-78.</citation>
    <PMID>25013389</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagao M, Nishikawa J, Ogawa R, Sasaki S, Nakamura M, Nishimura J, Goto A, Hashimoto S, Okamoto T, Suenaga M, Hamamoto Y, Sakaida I. Evaluation of the Diagnostic Ability of Optical Enhancement System in Early Gastric Cancer Demarcation. Gastroenterol Res Pract. 2016;2016:2439621. Epub 2016 Sep 28.</citation>
    <PMID>27774101</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoshen Li</investigator_full_name>
    <investigator_title>Director of Gastroenterology Dept</investigator_title>
  </responsible_party>
  <keyword>early gastric cancer</keyword>
  <keyword>Optical Enhancement</keyword>
  <keyword>Detection Rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

